The American firm is planning to begin human trials of its vaccine by the end of this month, after the drug cleared the previous stage, safely producing antibodies.

Reuters

2/5

Human trials

For Moderna, the next stage involves recruiting 30,000 participants for the trial, who will then be split into two groups, of which one will receive a placebo and the other will receive the vaccine.

Representative Image

Getty Images

3/5

Long run

These trials will run for two years, with scientists constantly monitoring progress to see that patients do not exhibit symptoms of COVID-19.

Despite the two year timeline, preliminary findings could be out much sooner.

Representative Image

Getty Images

4/5

Phase 1

Moderna’s Phase 3 announcement comes just as reports of its successful Phase 1 trial came out, with all 45 participants in the prior trial developing antibodies against the coronavirus.

Representative Image

AFP

5/5

Design

The vaccine is designed to use a genetic marker to grow a spike protein similar to the coronavirus within the human body and thereby trigger an immune response.

Representative Image

AFP